JP2000506723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000506723A5 JP2000506723A5 JP1997529893A JP52989397A JP2000506723A5 JP 2000506723 A5 JP2000506723 A5 JP 2000506723A5 JP 1997529893 A JP1997529893 A JP 1997529893A JP 52989397 A JP52989397 A JP 52989397A JP 2000506723 A5 JP2000506723 A5 JP 2000506723A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9603507.6A GB9603507D0 (en) | 1996-02-20 | 1996-02-20 | Antibody variants |
| GB9603507.6 | 1996-02-20 | ||
| PCT/GB1997/000472 WO1997031024A1 (en) | 1996-02-20 | 1997-02-20 | Antibody variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000506723A JP2000506723A (ja) | 2000-06-06 |
| JP2000506723A5 true JP2000506723A5 (enExample) | 2004-11-25 |
| JP4574750B2 JP4574750B2 (ja) | 2010-11-04 |
Family
ID=10789047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52989397A Expired - Lifetime JP4574750B2 (ja) | 1996-02-20 | 1997-02-20 | 抗体変異物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20020048578A1 (enExample) |
| EP (1) | EP0970127B1 (enExample) |
| JP (1) | JP4574750B2 (enExample) |
| AT (1) | ATE373016T1 (enExample) |
| AU (1) | AU723366B2 (enExample) |
| CA (1) | CA2246715C (enExample) |
| DE (1) | DE69738138T2 (enExample) |
| ES (1) | ES2294793T3 (enExample) |
| GB (1) | GB9603507D0 (enExample) |
| NZ (1) | NZ331299A (enExample) |
| WO (1) | WO1997031024A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1143006T3 (da) * | 1995-08-18 | 2008-07-14 | Morphosys Ip Gmbh | Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US6632926B1 (en) | 1998-11-18 | 2003-10-14 | Genentech, Inc. | Antibody variants |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| AU9399501A (en) * | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
| US20040109855A1 (en) * | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| JPWO2004087210A1 (ja) * | 2003-03-31 | 2006-06-29 | 麒麟麦酒株式会社 | 抗ｃｄ５２抗体による調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物 |
| EP1756278B1 (en) * | 2004-05-19 | 2008-09-17 | MediGene Ltd. | Method of improving t cell receptors |
| WO2006100449A1 (en) * | 2005-03-19 | 2006-09-28 | Medical Research Council | Improvements in or relating to treatment and prevention of viral infections |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| CN101820898B (zh) * | 2007-05-16 | 2013-10-30 | 中国抗体制药有限公司 | 互补决定区（CDRs）功能人源化 |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| JP5861223B2 (ja) | 2009-02-23 | 2016-02-16 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | プロタンパク質およびその使用方法 |
| RU2603743C2 (ru) | 2009-05-13 | 2016-11-27 | Джензим Корпорейшн | Иммуноглобулины k cd52 человека |
| US8685896B2 (en) | 2009-05-29 | 2014-04-01 | Morphosys Ag | Collection and methods for its use |
| KR101938021B1 (ko) | 2010-11-19 | 2019-01-11 | 모르포시스 아게 | 집합 및 집합의 이용방법 |
| GB201109238D0 (en) * | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
| US9494597B2 (en) * | 2012-04-02 | 2016-11-15 | Ab Biosciences, Inc. | Human control antibodies and uses therefor |
| WO2013163631A2 (en) | 2012-04-27 | 2013-10-31 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| US20160030384A1 (en) | 2013-04-09 | 2016-02-04 | Boston Biomedical, Inc. | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| US20160120158A1 (en) * | 2014-11-03 | 2016-05-05 | The Johns Hopkins University | Compositions and methods for the study and treatment of acute kidney injury |
| JP2018521979A (ja) | 2015-06-03 | 2018-08-09 | ボストン バイオメディカル， インコーポレイテッド | 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物 |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル， インコーポレイテッド | がんを処置するための方法 |
| WO2020223273A2 (en) | 2019-04-30 | 2020-11-05 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Compositions and methods for modulation of antibody activity |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5846534A (en) * | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| AU618989B2 (en) * | 1988-02-12 | 1992-01-16 | British Technology Group Limited | Improvements in or relating to antibodies |
| US5858725A (en) * | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DK0610447T3 (da) * | 1991-10-15 | 1999-08-23 | Btg Int Ltd | CDw52-specifikt antistof til behandling af T-cellemedieret inflammation af leddene |
| GB9125768D0 (en) * | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
-
1996
- 1996-02-20 GB GBGB9603507.6A patent/GB9603507D0/en active Pending
-
1997
- 1997-02-20 ES ES97905226T patent/ES2294793T3/es not_active Expired - Lifetime
- 1997-02-20 CA CA002246715A patent/CA2246715C/en not_active Expired - Fee Related
- 1997-02-20 AT AT97905226T patent/ATE373016T1/de not_active IP Right Cessation
- 1997-02-20 EP EP97905226A patent/EP0970127B1/en not_active Expired - Lifetime
- 1997-02-20 JP JP52989397A patent/JP4574750B2/ja not_active Expired - Lifetime
- 1997-02-20 DE DE69738138T patent/DE69738138T2/de not_active Expired - Lifetime
- 1997-02-20 WO PCT/GB1997/000472 patent/WO1997031024A1/en not_active Ceased
- 1997-02-20 NZ NZ331299A patent/NZ331299A/xx not_active IP Right Cessation
- 1997-02-20 US US09/125,460 patent/US20020048578A1/en not_active Abandoned
- 1997-02-20 AU AU18851/97A patent/AU723366B2/en not_active Ceased
-
2005
- 2005-07-14 US US11/180,631 patent/US8440190B2/en not_active Expired - Fee Related